Kidney Cancer Drugs Market Size, Growth and Forecast Analysis Report till 2022

The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Radiant Insights, Inc., registering a CAGR of 5.4% during the forecast period. Market growth is largely driven by factors such as availability of novel drugs and presence of a strong pipeline. Growth can also be attributed to rise in incidence of renal cancer due to growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.

In 2012, kidney cancer was the 13th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.

Request a Free Sample Copy of this Report @ https://www.radiantinsights.com/research/kidney-cancer-drugs-market/request-sample

Further key findings from the report suggest:

• Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth

• Novel agents have expanded market opportunities through larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected their rapid uptake and expansion of indications

• The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy)

• U.S. accounted for more than 35.0% of the market in 2016 due to increasing incidence of renal cell carcinoma and presence of key manufacturers in the country. On the other hand, surge in kidney cancer screening is a key driver in markets such as EU

• Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in elderly population, and improvement in diagnostic technologies

• Some of the key players operating in this market are Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, and Exelixis. Collaborations for development, broader product portfolios, and regional expansion in emerging markets are key strategic undertakings of these companies to increase market share.

Download Full Research Report @ https://www.radiantinsights.com/research/kidney-cancer-drugs-market

Table of Contents

Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1. Disease Primer
3.2. Epidemiology
Chapter 4 Global Market Overview
4.1 Market by Therapeutic Class
4.2 Market Size and Forecast 2016 – 2022
4.3 Market Share Distribution, by Company 2016 – 2022
4.4 Sales Performance, by Pharmacologic Class
4.5 Market Dynamics and Brand Strategies
4.6 Patent Expiry Analysis
4.7 Kidney Cancer Drugs Market: Drivers and Restraints
4.7.1 Drivers
4.7.2 Challenges
4.8 M&A, Deal Landscape (2013 – 2017 YTD)
4.8.1 Mergers & Acquisitions
4.8.2 Deals Landscape
4.9 Evolution of Biosimilars
4.10 Emerging Markets

About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Email: sales@radiantinsights.com
Phone: (415) 349-0054
Toll Free: 1-888-928-9744
Address: 201 Spear Street 1100, Suite 3036,
City: San Francisco
State: California
Country: United States

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.